Thomas P Miller

  • 19295 Citations
  • 58 h-Index
1978 …2016

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article

Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues

Rimsza, L. M., Wright, G., Schwartz, M., Chan, W. C., Jaffe, E. S., Gascoyne, R. D., Campo, E., Rosenwald, A., Ott, G., Cook, J. R., Tubbs, R. R., Braziel, R. M., Delabie, J., Miller, T. P. & Staudt, L. M., Jun 1 2011, In : Clinical Cancer Research. 17, 11, p. 3727-3732 6 p.

Research output: Contribution to journalArticle

51 Scopus citations

A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): A Southwest Oncology Group study

Fisher, R. I., Dahlberg, S., Nathwani, B. N., Banks, P. M., Miller, T. P. & Grogan, T. M., Jan 1 1995, In : Blood. 85, 4, p. 1075-1082 8 p.

Research output: Contribution to journalArticle

Open Access
307 Scopus citations

A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine- tositumomab

Press, O. W., Unger, J. M., Rimsza, L. M., Friedberg, J. W., Leblanc, M., Czuczman, M. S., Kaminski, M., Braziel, R. M., Spier, C., Gopal, A. K., Maloney, D. G., Cheson, B. D., Dakhil, S. R., Miller, T. P. & Fisher, R. I., Dec 1 2013, In : Clinical Cancer Research. 19, 23, p. 6624-6632 9 p.

Research output: Contribution to journalArticle

24 Scopus citations

Activity of esorubicin in recurrent malignant lymphoma: A southwest oncology group study

Miller, T. P., Dahlberg, S., Salmon, S. E., Williamson, S. K., Belt, R. J., Dana, B. W. & Fisher, R. I., Jan 1 1991, In : Journal of Clinical Oncology. 9, 7, p. 1204-1209 6 p.

Research output: Contribution to journalArticle

Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment

Qi, W., Spier, C., Liu, X., Agarwal, A., Cooke, L. S., Persky, D. O., Chen, D., Miller, T. P. & Mahadevan, D., Apr 2013, In : Leukemia Research. 37, 4, p. 434-439 6 p.

Research output: Contribution to journalArticle

39 Scopus citations

Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2

Mahadevan, D., Morales, C., Cooke, L. S., Manziello, A., Mount, D. W., Persky, D. O., Fisher, R. I., Miller, T. P. & Qi, W., Jun 3 2014, In : PloS one. 9, 6, e95184.

Research output: Contribution to journalArticle

25 Scopus citations

A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911

Press, O. W., Unger, J. M., Braziel, R. M., Maloney, D. G., Miller, T. P., LeBlanc, M., Gaynor, E. R., Rivkin, S. E. & Fisher, R. I., Sep 1 2003, In : Blood. 102, 5, p. 1606-1612 7 p.

Research output: Contribution to journalArticle

151 Scopus citations
47 Scopus citations

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma

Leonard, J. P., Friedberg, J. W., Younes, A., Fisher, D., Gordon, L. I., Moore, J., Czuczman, M., Miller, T., Stiff, P., Cheson, B. D., Forero-Torres, A., Chieffo, N., McKinney, B., Finucane, D. & Molina, A., Jul 2007, In : Annals of Oncology. 18, 7, p. 1216-1223 8 p.

Research output: Contribution to journalArticle

108 Scopus citations

A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease

Miller, T. P., Chase, E. M., Dorr, R., Dalton, W. S., Lam, K. S. & Salmon, S. E., Jan 1 1998, In : Anti-cancer drugs. 9, 2, p. 135-140 6 p.

Research output: Contribution to journalArticle

25 Scopus citations

A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study

Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., Glick, J. H., Coltman, C. A. & Miller, T. P., 1994, In : Annals of Oncology. 5, SUPPL. 2, p. 91-95 5 p.

Research output: Contribution to journalArticle

Open Access
64 Scopus citations

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213

Bernstein, S. H., Epner, E., Unger, J. M., LeBlanc, M., Cebula, E., Burack, R., Rimsza, L., Miller, T. P. & Fisher, R. I., Jun 1 2013, In : Annals of Oncology. 24, 6, p. 1587-1593 7 p.

Research output: Contribution to journalArticle

76 Scopus citations

A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520

Puvvada, S. D., Li, H., Rimsza, L. M., Bernstein, S. H., Fisher, R. I., LeBlanc, M., Schmelz, M., Glinsmann-Gibson, B., Miller, T. P., Maddox, A. M., Friedberg, J. W., Smith, S. M. & Persky, D. O., Jan 12 2016, (Accepted/In press) In : Leukemia and Lymphoma. p. 1-11 11 p.

Research output: Contribution to journalArticle

18 Scopus citations

A phase II study of bisantrene in malignant lymphomas - A southwest oncology group study

Miller, T. P., Cowan, J. D., Neilan, B. A. & Jones, S. E., Jan 1 1986, In : Cancer Chemotherapy And Pharmacology. 16, 1, p. 67-69 3 p.

Research output: Contribution to journalArticle

3 Scopus citations

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108

Stopeck, A. T., Unger, J. M., Rimsza, L. M., Bellamy, W. T., Iannone, M., Persky, D., Leblanc, M., Fisher, R. & Miller, T., Aug 17 2009, In : Leukemia and Lymphoma. 50, 5, p. 728-735 8 p.

Research output: Contribution to journalArticle

83 Scopus citations

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis

Tome, M. E., Johnson, D. B. F., Rimsza, L. M., Roberts, R. A., Grogan, T. M., Miller, T. P., Oberley, L. W. & Briehl, M. M., Nov 15 2005, In : Blood. 106, 10, p. 3594-3601 8 p.

Research output: Contribution to journalArticle

73 Scopus citations

A southwest oncology group perspective on the revised European-American lymphoma classification

Grogan, T. M., Miller, T. P., Fisher, R. I. & Graff, J. C., Jan 1 1997, In : Hematology/Oncology Clinics of North America. 11, 5, p. 819-846 28 p.

Research output: Contribution to journalArticle

11 Scopus citations

A Southwest Oncology Group phase II evaluation of fluderabine monophosphate in sarcoma

Grever, M. R., Benedetti, J., Balcerzak, S. P., Taylor, S. A., Miller, T. P. & Dakhil, S. R., Sep 1 1994, In : Investigational New Drugs. 12, 3, p. 259-261 3 p.

Research output: Contribution to journalArticle

1 Scopus citations

AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas

Qi, W., Liu, X., Cooke, L. S., Persky, D. O., Miller, T. P., Squires, M. & Mahadevan, D., Jun 15 2012, In : International Journal of Cancer. 130, 12, p. 2997-3005 9 p.

Research output: Contribution to journalArticle

30 Scopus citations

Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma

Mahadevan, D., Stejskal, A., Cooke, L. S., Manziello, A., Morales, C., Persky, D. O., Fisher, R. I., Miller, T. P. & Qi, W., Apr 15 2012, In : Clinical Cancer Research. 18, 8, p. 2210-2219 10 p.

Research output: Contribution to journalArticle

44 Scopus citations

Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma

Qi, W., Cooke, L. S., Liu, X., Rimsza, L., Roe, D. J., Persky, A. M. D. O., Miller, T. P. & Mahadevan, D., Apr 1 2011, In : Biochemical Pharmacology. 81, 7, p. 881-890 10 p.

Research output: Contribution to journalArticle

67 Scopus citations

Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma

Stiff, P. J., Unger, J. M., Cook, J. R., Constine, L. S., Couban, S., Stewart, D. A., Shea, T. C., Porcu, P., Winter, J. N., Kahl, B. S., Miller, T. P., Tubbs, R. R., Marcellus, D., Friedberg, J. W., Barton, K. P., Mills, G. M., LeBlanc, M., Rimsza, L. M., Forman, S. J. & Fisher, R. I., Jan 1 2013, In : New England Journal of Medicine. 369, 18, p. 1681-1690 10 p.

Research output: Contribution to journalArticle

192 Scopus citations

Chemohormonal therapy for advanced breast cancer with tamoxifen, adriamycin, and cyclophosphamide (TAC)

Ahmann, F. R., Jones, S. E., Moon, T. E., Hammond, N., Miller, T. P. & Durie, B. G. M., Aug 15 1985, In : Cancer. 56, 4, p. 730-737 8 p.

Research output: Contribution to journalArticle

4 Scopus citations

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma

Miller, T. P., Dahlberg, S., Cassady, J. R., Adelstein, D. J., Spier, C. M., Grogan, T. M., LeBlanc, M., Carlin, S., Chase, E. & Fisher, R. I., Jul 2 1998, In : New England Journal of Medicine. 339, 1, p. 21-26 6 p.

Research output: Contribution to journalArticle

803 Scopus citations

CHEMOTHERAPY OF LOCALISED HISTIOCYTIC LYMPHOMA

Miller, T. P. & Jones, S. E., Feb 17 1979, In : The Lancet. 313, 8112, p. 358-360 3 p.

Research output: Contribution to journalArticle

57 Scopus citations

Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: A southwest oncology group study

Jones, S. E., Grozea, P. N., Miller, T. P., Van Slyck, E. J., Balcerzak, S. P., Costanzi, J. J., Morrison, F. S., Eyre, H. J., Fabian, C. J. & Dabich, L., Jan 1 1985, In : Journal of Clinical Oncology. 3, 10, p. 1318-1324 7 p.

Research output: Contribution to journalArticle

54 Scopus citations

Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: A Southwest Oncology Group study

Weick, J. K., Dahlberg, S., Fisher, R. I., Dana, B., Miller, T. P., Balcerzak, S. P. & Pierce, H. I., Jan 1 1991, In : Journal of Clinical Oncology. 9, 5, p. 748-753 6 p.

Research output: Contribution to journalArticle

36 Scopus citations

Combination of fludarabine and mitoxantrone in untreated stages III and IV low-grade lymphoma: S9501

Velasquez, W. S., Lew, D., Grogan, T. M., Spiridonidis, C. H., Balcerzak, S. P., Dakhil, S. R., Miller, T. P., Lanier, K. S., Chapman, R. A. & Fisher, R. I., May 15 2003, In : Journal of Clinical Oncology. 21, 10, p. 1996-2003 8 p.

Research output: Contribution to journalArticle

50 Scopus citations

Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma

Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., Glick, J. H., Coltman, C. A. & Miller, T. P., Apr 8 1993, In : New England Journal of Medicine. 328, 14, p. 1002-1006 5 p.

Research output: Contribution to journalArticle

1895 Scopus citations

Comparison of lymphangiography and computed tomography scanning in evaluating abdominal disease in stages III and IV Hodgkin's disease: A southwest oncology group study

Mansfield, C. M., Fabian, C., Jones, S., Van Slyck, E. J., Grozea, P., Morrison, F., Miller, T. P., Seibert, C. & Ayyangar, K., Dec 1 1990, In : Cancer. 66, 11, p. 2295-2299 5 p.

Research output: Contribution to journalArticle

35 Scopus citations
2 Scopus citations

Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer - A Southwest Oncology Group study

Collins, C., Higano, C. S., Livingston, R. B., Griffin, B. R., Keppen, M. D. & Miller, T. P., Aug 1 1989, In : Cancer Chemotherapy And Pharmacology. 24, 2, p. 128-132 5 p.

Research output: Contribution to journalArticle

1 Scopus citations

Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: Relationship to HLA expression and host immunocompetence

List, A. F., Spier, C. M., Miller, T. P. & Grogan, T. M., Mar 1993, In : Leukemia. 7, 3, p. 398-403 6 p.

Research output: Contribution to journalArticle

45 Scopus citations
9 Scopus citations

Diffuse small cleaved-cell lymphoma: A heterogeneous disease with distinct immunobiologic subsets

Leith, C. P., Spier, C. M., Grogan, T. M., Gonzales, G., Rangel, C. S., Rybski, J. A., Matzner, M. & Miller, T. P., Jan 1 1992, In : Journal of Clinical Oncology. 10, 8, p. 1259-1265 7 p.

Research output: Contribution to journalArticle

15 Scopus citations

Directed indices for exploring gene expression data

LeBlanc, M., Kooperberg, C., Grogan, T. M. & Miller, T. P., Apr 12 2003, In : Bioinformatics. 19, 6, p. 686-693 8 p.

Research output: Contribution to journalArticle

9 Scopus citations

Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: A phase II study of the Southwest Oncology Group (SWOG 9349)

Blayney, D. W., LeBlanc, M. L., Grogan, T., Gaynor, E. R., Chapman, R. A., Spiridonidis, C. H., Taylor, S. A., Bearman, S. I., Miller, T. P. & Fisher, R. I., Jul 1 2003, In : Journal of Clinical Oncology. 21, 13, p. 2466-2473 8 p.

Research output: Contribution to journalArticle

68 Scopus citations

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy

Dalton, W. S., Grogan, T. M., Meltzer, P. S., Scheper, R. J., Durie, B. G. M., Taylor, C. W., Miller, T. P. & Salmon, S. E., Jan 1 1989, In : Journal of Clinical Oncology. 7, 4, p. 415-424 10 p.

Research output: Contribution to journalArticle

513 Scopus citations

Effectiveness of first-line management strategies for stage I follicular lymphoma: Analysis of the National Lymphocare Study

Friedberg, J. W., Byrtek, M., Link, B. K., Flowers, C., Taylor, M., Hainsworth, J., Cerhan, J. R., Zelenetz, A. D., Hirata, J. & Miller, T. P., Sep 20 2012, In : Journal of Clinical Oncology. 30, 27, p. 3368-3375 8 p.

Research output: Contribution to journalArticle

96 Scopus citations

Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience

Dixon, D. O., Neilan, B., Jones, S. E., Lipschitz, D. A., Miller, T. P., Grozea, P. N. & Wilson, H. E., Jan 1 1986, In : Journal of Clinical Oncology. 4, 3, p. 295-305 11 p.

Research output: Contribution to journalArticle

314 Scopus citations

Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A southwest oncology group study

Miller, T. P., Chen, T. T., Coltman, C. A., O'Bryan, R. M., Vance, R. B., Weiss, G. B., Fletcher, W. S., Stephens, R. L. & Livingston, R. B., Jan 1 1986, In : Journal of Clinical Oncology. 4, 4, p. 502-508 7 p.

Research output: Contribution to journalArticle

40 Scopus citations

Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay

Ludwig, R., Alberts, D. S., Miller, T. P. & Salmon, S. E., Apr 1 1984, In : Cancer Chemotherapy And Pharmacology. 12, 3, p. 135-141 7 p.

Research output: Contribution to journalArticle

29 Scopus citations

Examination of the follicular lymphoma international prognostic index (FLIPI) in the national lymphocare study (NLCS): A prospective US patient cohort treated predominantly in community practices

Nooka, A. K., Nabhan, C., Zhou, X., Taylor, M. D., Byrtek, M., Miller, T. P., Friedberg, J. W., Zelenetz, A. D., Link, B. K., Cerhan, J. R., Dillon, H., Sinha, R., Shenoy, P. J., Levy, D., Dawson, K., Hirata, J. H. & Flowers, C. R., Feb 1 2013, In : Annals of Oncology. 24, 2, p. 441-448 8 p., mds429.

Research output: Contribution to journalArticle

37 Scopus citations
27 Scopus citations

Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi): A Southwest Oncology Group study

Miller, T. P., Weick, J. K., Grozea, P. N. & Carlin, D. A., Jan 1 1982, In : Cancer Treatment Reports. 66, 3, p. 553-556 4 p.

Research output: Contribution to journalArticle

11 Scopus citations

Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): A Southwest Oncology Group Study

Miller, T. P., Vance, R. B., Ahmann, F. R. & Rodney, S. R., Jan 1 1986, In : Cancer Treatment Reports. 70, 9, p. 1101-1104 4 p.

Research output: Contribution to journalArticle

22 Scopus citations

External beam radiation therapy in the treatment of patients with extranodal stage IA non-Hodgkin's lymphoma

Briggs, J. H., Algan, Ö., Miller, T. P. & Oleson, J. R., Feb 18 2002, In : American Journal of Clinical Oncology: Cancer Clinical Trials. 25, 1, p. 34-37 4 p.

Research output: Contribution to journalArticle

7 Scopus citations

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

Persky, D. O., Dornan, D., Goldman, B. H., Braziel, R. M., Fisher, R. I., LeBlanc, M., Maloney, D. G., Press, O. W., Miller, T. P. & Rimsza, L. M., Jun 1 2012, In : Haematologica. 97, 6, p. 937-942 6 p.

Research output: Contribution to journalArticle

44 Scopus citations

Follicular lymphomas: Do histologic subtypes predict outcome?

Miller, T. P., LeBlanc, M., Grogan, T. M., Fisher, R. I. & Graff, J. C., Jan 1 1997, In : Hematology/Oncology Clinics of North America. 11, 5, p. 893-900 8 p.

Research output: Contribution to journalArticle

43 Scopus citations

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP

Rimsza, L. M., LeBlanc, M. L., Unger, J. M., Miller, T. P., Grogan, T. M., Persky, D. O., Mattel, R. R., Sabalos, C. M., Seligmann, B., Braziel, R. M., Campo, E., Rosenwald, A., Connors, J. M., Sehn, L. H., Johnson, N. & Gascoyne, R. D., Oct 15 2008, In : Blood. 112, 8, p. 3425-3433 9 p.

Research output: Contribution to journalArticle

111 Scopus citations